Pfizer buys Arena Pharmaceuticals to gain control over cardiovascular “treatments” that are in high demand after COVID jabs
You read that right. With the recent completion of their $6.7 billion purchase of Arena Pharmaceuticals, Pfizer, the head of the pharmaceutical drug cartel and manufacturer of the most harmful “vaccine” ever invented for humans, has gained influence over cardiovascular “treatments” for the disastrous health trauma brought on by the Wuhan coronavirus (COVID-19) vascular-clogging clot shots they themselves produce. Arena Pharma produces pharmaceuticals that purport to “treat” disorders caused by vaccination injuries that are immune-inflammatory. In other words, Pfizer, the criminal cartel pharma corporation, is now literally causing injuries with its goods and then peddling pharmaceuticals to “treat” (or worsen) those injuries. The medical-industrial complex refers to this situation as a “problem-reaction-solution” crisis.
In response to the merger, Pfizer’s chief business innovation officer stated, “We believe this transaction represents the best next step for both patients and shareholders.” This is due to the fact that the merger will allow investors to profit from the vascular clotting caused by the Pfizer COVID injections’ spike protein prions, and the corporation can now profit from the treatment of the resulting compounded health disorders in the vascular systems of a few hundred million Americans.
Because spike protein syndrome causes persistent inflammation, a drug called Etrasimod, which treats inflammatory diseases, is at the centre of Pfizer’s takeover of Arena Pharmaceuticals. Temanogrel is a medication used to treat microvascular blockage. Let’s say that again. occlusion of the microvasculature. That is the primary issue that the Pfizer clot shots generated, which explains why myocarditis cases have exploded globally and nationally ever since the introduction of the mRNA spike protein stabs. Once more, it exemplifies the business model of problem-reaction-solution. Temanogrel, also referred to by the trade name APD791, is employed to treat arterial thrombosis.
Pfizer will now “treat” the cardiovascular nightmares they created with the mRNA jabs
The adverse events that follow the administration of COVID-19 mRNA vaccines, as documented by clinical trials, have recently been published in March 2023 by the National Institute of Health, under the National Library of Medicine and National Center for Biotechnology Information, including a systematic review of… get ready for it… “cardiovascular complication, thrombosis, and thrombocytopenia.”
Cardiovascular complications following the first OR second dose of mRNA gene-mutation injections have been widely reported. These complications include “pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism.”
Recognize that arterial thrombosis, which can lead to acute coronary syndrome or stroke, is the formation of blood clots or “thrombus” inside an artery that restricts or blocks the flow of blood. This is what we see in the news with athletes, members of the military, and celebrities who receive clot injections and “die suddenly.” That is a crucial factor in Pfizer’s recent purchase of Arena Pharmaceuticals. Just follow the money and do the math.
Chris Cabell, MD, Arena’s senior vice president, just stated, “With approximately 10 million DHF patient hospital visits expected in the U.S. by 2025 and few viable treatment options, we believe that APD418 has the potential to make a significant impact for these patients.” You see, they are predicting at least 10 million new patients who will be suffering from cardiovascular obstructions.
Remember, Temanogrel received FDA fast track approval back in 2020, meaning they basically skipped (or skewed) clinical trials and went straight to market. According to the acquisition terms, Arena Pharma was valued at $100 in cash per share, and Arena is now a wholly owned subsidiary of Pfizer. Bookmark Vaccines.news to your favorite independent websites for updates on Long-Vax-Syndrome and clot shot blood clogging that Pfizer will be “treating ” with their newly acquired drug company.
{Source: Natural News}
About Author
